Ceruti Samuele, Glotta Andrea, Adamson Harriet, Mauri Romano, Molnar Zsolt
Critical Care Department, Clinica Luganese Moncucco, Lugano, Switzerland.
CytoSorbents Europe GmbH, Berlin, Germany.
Case Rep Hematol. 2021 Aug 20;2021:5539126. doi: 10.1155/2021/5539126. eCollection 2021.
Acute hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease, with an annual incidence of 1 : 800,000 people. The disease is characterized by a cytokine storm, with concomitant macrophage and natural killer (NK) cell activation; death can occur from multiple organ failure or complications such as bleeding diathesis. Therefore, HLH treatment remains a challenging one. We hereby present a case of a 76-year-old man with severe HLH in whom hemoadsorption was successfully applied. Due to the failure of the immunomodulatory therapy , continuous venovenous hemodiafiltration therapy with the CytoSorb® adsorber was successfully applied for 48 hours. Upon therapy discontinuation, the biological and clinical condition reverted, unfortunately evolving towards the patient's death.
急性噬血细胞性淋巴组织细胞增生症（HLH）是一种危及生命的疾病，年发病率为1：800000。该疾病的特征是细胞因子风暴，伴有巨噬细胞和自然杀伤（NK）细胞激活；死亡可能由多器官功能衰竭或诸如出血素质等并发症引起。因此，HLH的治疗仍然具有挑战性。我们在此报告一例76岁患有严重HLH的男性患者，成功应用了血液吸附治疗。由于免疫调节治疗失败，使用CytoSorb®吸附器的持续静静脉血液透析滤过治疗成功应用了48小时。治疗停止后，生物学和临床状况恢复，但不幸的是病情逐渐发展至患者死亡。
